103 related articles for article (PubMed ID: 4004281)
1. [Phase I study of recombinant human interferon alpha A (Ro 22-8181) in patients with malignant tumors].
Taguchi T
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):456-64. PubMed ID: 4004281
[TBL] [Abstract][Full Text] [Related]
2. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in skin malignant tumors].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):936-42. PubMed ID: 2985007
[TBL] [Abstract][Full Text] [Related]
3. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in malignant brain tumors].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):913-20. PubMed ID: 3885862
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in hematological malignancies].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):928-35. PubMed ID: 3885864
[TBL] [Abstract][Full Text] [Related]
5. [Phase I study of human lymphoblastoid alpha-interferon on malignant tumor].
Furue H
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):977-83. PubMed ID: 3963861
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
7. [Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma].
Furue H
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1625-9. PubMed ID: 3896154
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy of recombinant human leukocyte A interferon (rIFN-alpha A) on malignant tumors of the urogenital tract].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):921-7. PubMed ID: 3885863
[TBL] [Abstract][Full Text] [Related]
9. [A cooperative phase I-II study of HLBI in patients with malignant tumors].
Kimura K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1324-31. PubMed ID: 6329104
[TBL] [Abstract][Full Text] [Related]
10. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
11. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
Silver HK; Connors JM; Salinas FA
Cancer Treat Rep; 1985; 69(7-8):743-50. PubMed ID: 4016785
[TBL] [Abstract][Full Text] [Related]
12. [Phase II study of recombinant human leukocyte A interferon on urogenital cancer patients].
Yoshimoto J; Tsushima T; Matsumura Y; Ohmori H; Saito N; Tanaka H; Asahi T; Ohkita K; Tanahashi T; Nanba K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):465-70. PubMed ID: 4004282
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
Kasamatsu T; Ohmi K; Takeuchi S; Takamizawa H; Matsuzawa M; Kawana T; Ueda K; Kubo H; Tsumuji Y; Kawashima Y
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1656-60. PubMed ID: 3896157
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
15. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia].
Ichimaru M; Kamihira S; Moriuchi Y; Kuraishi Y; Usui N; Toki H; Okabe K; Niho Y; Shibuya T; Umei T
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2975-81. PubMed ID: 3052302
[TBL] [Abstract][Full Text] [Related]
17. [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
Furue H; Machida T; Masaoka T; Ikeda S
Gan To Kagaku Ryoho; 1997 Jan; 24(1):67-75. PubMed ID: 9020948
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of Wellferon (human lymphoblastoid alpha-interferon) as cancer therapy: clinical results.
Sarna G; Figlin R; McCarthy S
J Biol Response Mod; 1983; 2(2):187-95. PubMed ID: 6644335
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
20. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
